摘要
目的探讨X射线交错互补修复基因3(XRCC3)在人脑胶质瘤中的表达及其临床意义。方法随机选取65例神经外科手术切除的胶质瘤标本、10例颅脑外伤手术切除的正常脑组织及瘤旁证实为正常脑组织标本30例,采用免疫组织化学方法检测胶质瘤及正常脑组织标本中XRCC3的表达;分析XRCC3表达与胶质瘤临床病理参数之间的关系,绘制Kaplan-Meier生存曲线比较不同XRCC3表达水平胶质瘤患者的预后状况。结果正常脑组织XRCC3高表达率为20.0%,胶质瘤组织高表达率为50.8%,两者差异有统计学意义(P=0.017)。胶质瘤XRCC3表达与性别、年龄、肿瘤大小、部位、KPS评分无关(P均>0.05);病理分级Ⅲ~Ⅳ级胶质瘤XRCC3高表达率为64.7%,Ⅰ~Ⅱ级高表达率为35.5%,二者差异有统计学意义(P=0.019)。XRCC3低表达胶质瘤患者生存时间(68±3.08)个月,高表达生存时间(24±7.10)个月,两者生存时间比较差异有统计学意义(P=0.003)。结论胶质瘤组织XRCC3表达增高,且XRCC3表达与胶质瘤病理分级及患者生存期相关,有可能成为新的胶质瘤预后预测因子。
Objective To investigate the expression and clinical significance of X-ray repair cross-complementing group 3(XRCC3)in human glioma.Methods We randomly selected 65 cases of glioma specimens removed by neurosurgery,10 cases of normal brain tissues resected by craniocerebral trauma,and 30 cases of paraneoplasticnormal brain tissues.Immunohistochemistry was used to detect the expression of XRCC3 in glioma and normal brain tissues.The relationship between XRCC3 and clinicopathological parameters was analyzed,and the Kaplan-Meier curve was drawn to compare the prognosis of patients with different expression levels of XRCC3.Results The high expression rate of XRCC3 in the normal brain tissues was 20.0%,and the high expression rate of glioma tissues was 50.8%,with statistically significant difference(P=0.017).No significant correlations were observed between the expression of XRCC3 and other clinical factors,including gender,age,tumor diameter,location and KPS score(all P>0.05).The high expression rate of XRCC3 in pathological gradeⅢ-Ⅳglioma accounted for 64.7%,higher than that in pathological gradeⅠ-Ⅱ(35.5%);with statistically significantdifference(P=0.019).The survival time of patients with low expression of XRCC3 was(68±3.08)months,and that of patients with high expression of glioma was(24±7.10)months;there was statistically significant difference between these two groups(P=0.003).Conclusion The expression of XRCC3 increases in glioma tissues,and the expression of XRCC3 is related to the pathological grade and survival time,which may become a new prognostic factor of glioma.
作者
张墨轩
冯帆
潘景臻
崔洪玮
张健
刘伟
ZHANG Moxuan;FENG Fan;PAN Jingzhen;CUI Hongwei;ZHANG Jian;LIU Wei(Weifang Medical University,Weifang 261053,China)
出处
《山东医药》
CAS
2019年第22期4-7,共4页
Shandong Medical Journal
基金
山东省医药卫生科技发展计划项目(2014WS0474
2017WS578)
关键词
胶质瘤
X射线交错互补修复基因3
病理分级
预后
glioma
X-ray repair cross-complementing group 3
pathological grade
prognosis
